Outcome of 49 Iraqi adult patients with Chronic Lymphocytic Leukemia treated with oral alkylating agent:
Background: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with an extremely variable course. Survival after diagnosis can range from months to decades and wide variability exists in the rate of disease progression and the incidence of disease-related complications among patients with...
Main Author: | Alaadin S. Naji |
---|---|
Format: | Article |
Language: | English |
Published: |
College of Medicine University of Baghdad
2012-07-01
|
Series: | مجلة كلية الطب |
Subjects: | |
Online Access: | http://iqjmc.uobaghdad.edu.iq/index.php/19JFacMedBaghdad36/article/view/740 |
Similar Items
-
Bendamustine: an Old Drug in the New Era for Patients with Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
by: Martina Bogeljić Patekar, et al.
Published: (2018-01-01) -
The Prognostic Value of CD49d Expression in Turkish Patients with Chronic Lymphocytic Leukemia
by: Ant Uzay, et al.
Published: (2012-12-01) -
Novel Agents in Chronic Lymphocytic Leukemia: New Combination Therapies and Strategies to Overcome Resistance
by: Moritz Fürstenau, et al.
Published: (2021-03-01) -
Infections in patients with chronic lymphocytic leukemia
by: Mariana Guarana, et al.
Published: (2023-07-01) -
Meningeal involvement in chronic lymphocytic leukemia
by: S. N. Menshakova, et al.
Published: (2022-11-01)